Document:

ampe_Ex4_5

		
			EXHIBIT 4.5
		

		
			DESCRIPTION OF CAPITAL STOCK
		

		
			General
		

		
			Our authorized capital stock consists of 300,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of undesignated preferred stock, $0.0001 par value, of which no preferred shares are issued or outstanding.
		

		
			The following summary description of our capital stock is based on the provisions of our certificate of incorporation and bylaws and the applicable provisions of the Delaware General Corporation Law. This information is qualified entirely by reference to the applicable provisions of our certificate of incorporation, bylaws and the Delaware General Corporation Law. For information on how to obtain copies of our certificate of incorporation and bylaws, please see “Where You Can Find Additional Information” and “Incorporation of Certain Information by Reference.”
		

		
			Common Stock
		

		
			As of February 14, 2020, there were 158,780,993 shares of our common stock outstanding. Holders of common stock will have voting rights for the election of our directors and all other matters requiring stockholder action,  except with respect to amendments to our certificate of incorporation that alter or change the powers, preferences, rights or other terms of any outstanding preferred stock if the holders of such affected series of preferred stock are entitled to vote on such an amendment. There is no cumulative voting with respect to the election of directors, with the result that the holders of more than 50% of the shares voted for the election of directors can elect all of the directors. Holders of common stock will be entitled to one vote per share on matters to be voted on by stockholders and also will be entitled to receive such dividends, if any, as may be declared from time to time by our board of directors in its discretion out of funds legally available therefor. The payment of dividends, if ever, on the common stock will be subject to the prior payment of dividends on any outstanding preferred stock, of which there is currently none. Upon our liquidation or dissolution, the holders of common stock will be entitled to receive pro rata all assets remaining available for distribution to stockholders after payment of all liabilities and provision for the liquidation of any shares of preferred stock at the time outstanding. Our stockholders have no conversion, preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to the common stock.
		

		
			Preferred Stock
		

		
			Pursuant to our certificate of incorporation, our board of directors has the authority, without further action by the stockholders (unless such stockholder action is required by applicable law or stock exchange listing rules), to designate and issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the designations, powers, preferences, privileges and relative participating, optional or special rights and the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, voting rights, terms of redemption and liquidation preferences, any or all of which may be greater than the rights of the common stock, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding.
		

		
			The board of directors, without stockholder approval, can issue preferred stock with voting, conversion or other rights that could adversely affect the voting power and other rights of the holders of common stock. Preferred stock could be issued quickly with terms designed to delay or prevent a change in control of our company or make removal of management more difficult. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of the common stock and may adversely affect the voting power of holders of common stock and reduce the likelihood that common stockholders will receive dividend payments and payments upon liquidation.
		

		
			
		

		
			

		 

		

		
			 
		

		
			Our board of directors will fix the designations, voting powers, preferences and rights of the each series, as well as the qualifications, limitations or restrictions thereof, of the preferred stock of each series that we offer under this prospectus and applicable prospectus supplements in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of that series of preferred stock. This description will include:
		

		
			 
		

		
			  the title and stated value;
		

		
			 
		

		
			  the number of shares we are offering;
		

		
			 
		

		
			  the liquidation preference per share;
		

		
			 
		

		
			  the purchase price per share;
		

		
			 
		

		
			  the dividend rate per share, dividend period and payment dates and method of calculation for dividends;
		

		
			 
		

		
			  whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate;
		

		
			 
		

		
			  our right, if any, to defer payment of dividends and the maximum length of any such deferral period;
		

		
			 
		

		
			  the procedures for any auction and remarketing, if any;
		

		
			 
		

		
			  the provisions for a sinking fund, if any;
		

		
			 
		

		
			  the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights;
		

		
			 
		

		
			  any listing of the preferred stock on any securities exchange or market;
		

		
			 
		

		
			  whether the preferred stock will be convertible into our common stock or other securities of ours, including depositary shares and warrants, and, if applicable, the conversion period, the conversion price, or how it will be calculated, and under what circumstances it may be adjusted;
		

		
			 
		

		
			  whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange period, the exchange price, or how it will be calculated, and under what circumstances it may be adjusted;
		

		
			 
		

		
			  voting rights, if any, of the preferred stock;
		

		
			 
		

		
			  preemption rights, if any;
		

		
			 
		

		
			  restrictions on transfer, sale or other assignment, if any;
		

		
			 
		

		
			  whether interests in the preferred stock will be represented by depositary shares;
		

		
			 
		

		
			  a discussion of any material or special United States federal income tax considerations applicable to the preferred stock;
		

		
			 
		

		
			  the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs;
		

		
			 
		

		
			  any limitations on issuances of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock being issued as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and
		

		
			 
		

		
			
		

		
			

		 

		

		
			 
		

		
			  any other specific terms, rights, preferences, privileges, qualifications or restrictions of the preferred stock.
		

		
			The General Corporation Law of the State of Delaware, the state of our incorporation, provides that the holders of preferred stock will have the right to vote separately as a class (or, in some cases, as a series) on an amendment to our certificate of incorporation if the amendment would change the par value or, unless the certificate of incorporation provided otherwise, the number of authorized shares of the class or change the powers, preferences or special rights of the class or series so as to adversely affect the class or series, as the case may be. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation.
		

		
			Delaware Anti-Takeover Law and Provisions of our Certificate of Incorporation and Bylaws
		

		
			Delaware Anti-Takeover Law.
		

		
			As a Delaware corporation, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which generally has an anti-takeover effect for transactions not approved in advance by our board of directors. This may discourage takeover attempts that might result in payment of a premium over the market price for the shares of common stock held by stockholders. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a three-year period following the time that such stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. A “business combination” includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. An “interested stockholder” is a person who, together with affiliates and associates, owns, or did own within three years prior to the determination of interested stockholder status, 15% or more of the corporation’s voting stock.
		

		
			Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:
		

		
			 
		

		
			  before the stockholder became interested, the board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; or
		

		
			 
		

		
			  upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) shares owned by:
		

		
			 
		

		
			    persons who are directors and also officers; and
		

		
			 
		

		
			    employee stock plans, in some instances; or
		

		
			 
		

		
			  at or after the time the stockholder became interested, the business combination was approved by the board of directors of the corporation and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.
		

		
			Staggered board of directors
		

		
			Our Delaware certificate of incorporation provides that our board of directors will be classified into three classes of directors of approximately equal size at a date selected by the board. Currently our board of directors is not classified. As a result, in most circumstances, a person can gain control of our board only by successfully engaging in a proxy contest at two or more annual meetings.
		

		
			Advance notice requirements for stockholder proposals and director nominations
		

		
			Our Delaware bylaws provide that stockholders seeking to bring business before our annual meeting of stockholders, or to nominate candidates for election as directors at our annual meeting of stockholders, must provide timely notice of their intent in writing. To be timely, a stockholder’s notice needs to be delivered to our principal executive offices not later than the close of business on the 90th day nor earlier than the close of business on the
		

		
			
		

		
			

		 

		

		
			 
		

		
			120th day prior to the first anniversary of the preceding year’s annual meeting of stockholders. Our bylaws also specify certain requirements as to the form and content of a stockholders’ meeting. These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders.
		

		
			Authorized but unissued shares
		

		
			Our authorized but unissued shares of common stock and preferred stock are available for future issuances without stockholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.
		

		
			Limitation on liability and indemnification of directors and officers
		

		
			Our Delaware certificate of incorporation and bylaws provide that our directors and officers will be indemnified by us to the fullest extent authorized by Delaware law as it now exists or may in the future be
		

		
			 amended, against all expenses and liabilities reasonably incurred in connection with their service for or on our behalf. Our bylaws permit us to secure insurance on behalf of any officer, director or employee for any liability arising out of his or her actions, regardless of whether Delaware law would permit indemnification.
		

		
			These provisions may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder’s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. We believe that these provisions, insurance and the indemnity agreements are necessary to attract and retain talented and experienced directors and officers.
		

		
			Other than the two putative class action lawsuits in the United States District Court in the Central District of California, Napoli v. Ampio Pharmaceuticals, Inc., et al., Case No. 2:15-cv-03474-TJH and Stein v. Ampio Pharmaceuticals, Inc., et al., Case No. 2:15-cv-03640-TJH described in our Annual Report on Form 10-K and filed with the SEC on March 16, 2017, there is no pending litigation or proceeding involving any of our directors or officers where indemnification by us would be required or permitted, nor are we aware of any threatened litigation or proceeding that might result in a claim for such indemnification. Insofar as indemnification for liabilities arising under the Securities Act of 1933, or the Act, may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.
		

		
			Transfer Agent and Registrar
		

		
			The transfer agent and registrar for our common stock is Corporate Stock Transfer, Inc., 3200 Cherry Creek Drive South, Suite 430, Denver, Colorado 80209.ampe_Ex10_11

		
			Exhibit 10.11
		

		
			 
		

		
			AMENDMENT NO. 3 TO HUMAN SERUM ALBUMIN INGREDIENT PURCHASE AND SALE AGREEMENT
		

		
			 
		

		
			This Amendment (this “Amendment”) No. 3 to the Human Serum Albumin Ingredient Purchase and Sale Agreement is made and entered into as of November 14, 2017 by and between Octapharma USA, Inc., a Virginia corporation (“Supplier”), and Ampio Pharmaceuticals, Inc., a Delaware corporation (“Customer”).  Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Original Agreement (as defined below).
		

		
			 
		

		
			RECITALS
		

		
			 
		

		
			WHEREAS, Customer and Supplier previously entered into that certain Human Serum Albumin Ingredient Purchase and Sale Agreement dated October 10, 2013 and an Amendment 1 thereto dated February 27, 2015 and Amendment 2 thereto dated October 8, 2015 (together, the “Original Agreement”); and
		

		
			 
		

		
			WHEREAS,  Customer and Supplier desire to amend the Original Agreement as set forth below.
		

		
			 
		

		
			AGREEMENT
		

		
			 
		

		
			NOW, THEREFORE, the parties hereto agree as follows:
		

		
			 
		

		
			1.          Amendments to the Original Agreement.
		

		
			a.        Customer and Supplier hereby agree that, notwithstanding anything to the contrary in the Original Agreement, (i) from the date of this Amendment through December 31, 2017, Customer shall have no obligation to purchase any Products and (ii) Supplier forgives any shortfalls in Customer’s minimum purchase commitments prior to the date of this Amendment and customers purchase commitment will extend until Dec 31, 2020 to account for shortfall in 2017.
		

		
			b.        Unless agreed upon by Octapharma due to further delay in customer’s product approval beyond Dec 31, 2017, Octapharma reserves the right to legally enforce the terms of this contract going forward until Dec 31, 2020. Octapharma also reserves the right to increase pricing no more than 5% of current contracted per bottle price beginning in 2018 to account for increased production costs.  The increase will be a one-time increase.
		

		
			2.          Miscellaneous.
		

		
			a.        Except as effected by this Amendment, the terms and provisions of the Original Agreement shall remain unchanged and in full force and effect.
		

		
			IN WITNESS WHEREOF, the undersigned has executed this Amendment No. 3 to the Human Serum Albumin Ingredient Purchase and Sale Agreement as of the date first written above.
		

		
			 
		

		
			
		

		
			

		 

		

		
			 
		

			
					
						 

					
					
						CUSTOMER:

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						AMPIO PHARMACEUTICALS, INC.

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						By:

					
					
						/s/ Thomas Chilcott

				
	
					
						 

					
					
						 

					
					
						Name:  Thomas Chilcott

				
	
					
						 

					
					
						 

					
					
						Title:    Chief Financial Officer

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						SUPPLIER:

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						OCTAPHARMA USA, INC.

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						By:

					
					
						/s/ Flemming Nielsen

				
	
					
						 

					
					
						 

					
					
						Name:  Flemming Nielsen

				
	
					
						 

					
					
						 

					
					
						Title:    President

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						AUTHORIZED DISTRIBUTOR:

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						NOVA BIOLOGICS, INC.

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						By:

					
					
						/s/ Michael Crowley, Sr.

				
	
					
						 

					
					
						 

					
					
						Name:  Michael Crowley, Sr.

				
	
					
						 

					
					
						 

					
					
						Title:    President & CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}]]